Disease · MONDO_0013730

graft versus host disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. graft versus host disease. Diseases, record MONDO_0013730. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013730

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: graft versus host disease; Open Targets
Open Targets ID: MONDO_0013730; Open Targets
Other names: GVH, GVHD, disease, graft-versus-host, disease, graft-vs-host, diseases, graft-versus-host, diseases, graft-vs-host, graft vs host disease, runt disease; Open Targets
Disease Ontology: DOID:0081267; Disease Ontology
MeSH: D006086; MeSH
NCI Thesaurus: C3063; NCI Thesaurus
Orphanet: ORPHA:39812; Orphanet
Highest stage of its drugs: Approval, for 10 of its 134 drugs, from ClinicalTrials.gov, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs134

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RUXOLITINIB	CHEMBL1789941	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	19	18	18	Drugs and targets
TACROLIMUS ANHYDROUS	CHEMBL269732	Small molecule	Approval	PMDA	18	16	16	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Approval	PMDA	11	9	9	Drugs and targets
BELUMOSUDIL	CHEMBL2005186	Small molecule	Approval	EMA Human Drugs and TTD	9	7	7	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Approval	TTD	8	7	7	Drugs and targets
AXATILIMAB	CHEMBL4594608	Antibody	Approval	ClinicalTrials.gov	5	5	5	Drugs and targets
RUXOLITINIB PHOSPHATE	CHEMBL1795071	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
BELUMOSUDIL MESYLATE	CHEMBL4802130	Small molecule	Approval	FDA	1	0	0	Drugs and targets
DOXRIBTIMINE	CHEMBL52609	Small molecule	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
MUROMONAB-CD3	CHEMBL1201608		Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 134

See all 134 drugs

Targets159

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	17	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	4	FK506-binding protein 1A inhibitor	Approval	https://conductscience.org/library/genes/2280	Drugs and targets
IL2RA	Interleukin-2 receptor	4	Interleukin-2 receptor agonist; Interleukin-2 receptor alpha chain antagonist; Interleukin-2 receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3559	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
HDAC1	Histone deacetylase	3	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	3	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	3	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets

1 to 10 of 159

See all 159 targets

Trials218

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03139604	GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease	Phase 3	439	2020-05-15	Graft-versus-host Disease (GVHD)	ITACITINIB, METHYLPREDNISOLONE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT03959241	TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)	Phase 3	431	2024-01-12	Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma	CYCLOPHOSPHAMIDE, METHOTREXATE, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT02345850	Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)	Phase 3	346	2021-12-21	Acute Leukemia, Myelodysplasia	CYCLOPHOSPHAMIDE, METHOTREXATE, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT01002742	Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)	Phase 3	236	2016-05-27	Graft-versus-Host Disease, Immune System Disorders	MYCOPHENOLATE MOFETIL, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00281879	Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer	Phase 2	200	2012-06-19	Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood	BUSULFAN, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOSPORINE, CYTARABINE, ETOPOSIDE, FILGRASTIM, FLUDARABINE PHOSPHATE, MELPHALAN, METHOTREXATE, METHYLPREDNISOLONE, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT02065869	Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant	Phase 1/2	187	2023-01-04	Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell	RIVOGENLECLEUCEL	Its record names the disease	ClinicalTrials.gov
NCT00929695	Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease	Phase 3	164	2014-10-09	Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia	METHYLPREDNISOLONE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01106833	Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)	Phase 2/3	151	2018-08-14	Chronic GVHD	PREDNISONE, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00926575	Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)	Phase 3	140	2013-12-06	Acute Gastrointestinal Graft vs Host Disease	BECLOMETHASONE DIPROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT01754389	Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant	Phase 2	138	2017-07-18	Graft Versus Host Disease	BORTEZOMIB, METHOTREXATE, SIROLIMUS, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 218

See all 218 trials

Comparisons in its trials58

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of aGVHD Flares	42 of 219	48 of 220	439	NCT03139604	Trial comparisons
Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of Secondary Graft Failure	2 of 219	0 of 220	439	NCT03139604	Trial comparisons
Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Number of Treatment-emergent Adverse Events With INCB39110	208 of 215	214 of 216	431	NCT03139604	Trial comparisons
PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: deaths from any cause	58 of 214	70 of 217	431	NCT03959241	Trial comparisons
PTCY/Tacrolimus/MMF vs Tacrolimus/Methotrexate: serious adverse events	7 of 208	14 of 212	420	NCT03959241	Trial comparisons
Mycophenolate Mofetil vs Placebo: Incidence of Systemic Infections	81 of 116	77 of 119	235	NCT01002742	Trial comparisons
Mycophenolate Mofetil vs Placebo: Incidence of Epstein-Barr Virus (EBV)-Associated Lymphoma	6 of 116	4 of 119	235	NCT01002742	Trial comparisons
Mycophenolate Mofetil vs Placebo: Incidence of Topical/Non-absorbable Therapy	77 of 116	81 of 119	235	NCT01002742	Trial comparisons
Mycophenolate Mofetil vs Placebo: Incidence of GVHD Flares Requiring Increased Therapy	8 of 116	16 of 119	235	NCT01002742	Trial comparisons
Mycophenolate Mofetil vs Placebo: serious adverse events	13 of 116	13 of 119	235	NCT01002742	Trial comparisons

1 to 10 of 58

See all 58 comparisons in its trials

Papers from its trials73

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39438467	RESULT	1	PubMed
38991629	RESULT	1	PubMed
35668528	RESULT	1	PubMed
34218265	RESULT	1	PubMed
33536914	RESULT	1	PubMed
32242050	RESULT	1	PubMed
32119132	RESULT	1	PubMed
32043777	RESULT	1	PubMed
31958417	RESULT	1	PubMed
30808685	RESULT	1	PubMed

1 to 10 of 73

See all 73 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0013730

GET https://conductscience.org/api/diseases/v1/MONDO_0013730/drugs?page=2

API reference For AI assistants